Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2005 in advanced solid tumors
NCT07004296Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- May 2025
- Primary completion
- Jul 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HDM2005 in solid tumor, sponsored by Huadong Medicine. Primary endpoints: Incidence of Dose Limiting Toxicity at 28 days, Incidence and Severity of Adverse Events and 3 more. Started May 2025; status: recruiting.
02
Drugs
HDM2005
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07004296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07004296.